124I-labeled monoclonal antibody Mu 11-1F4 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
28	Systemic amyloidosis	2

28. Systemic amyloidosis

---

Clinical trials : 267 /  Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00807872 (ClinicalTrials.gov)	December 2008	11/12/2008	Radioimmunoimaging of AL Amyloidosis	Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4	Primary Amyloidosis	Biological: 124I-labeled monoclonal antibody Mu 11-1F4	University of Tennessee	FDA Office of Orphan Products Development	Completed	21 Years	90 Years	Both	40	Phase 1	United States
2	NCT01409148 (ClinicalTrials.gov)	November 2008	28/7/2011	Radioimmunoimaging of AL Amyloidosis	Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4	AL Amyloidosis	Biological: 124I-labeled monoclonal antibody Mu 11-1F4	University of Tennessee	Food and Drug Administration (FDA)	Completed	21 Years	90 Years	Both	38	Phase 1	United States